Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 477 Jan 1 – Oct 25, 2026
- Disclosed funding
- $20.2B 403 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| R Transforms carbon into essential materials using proprietary enzyme platform | $7.5M | Undisclosed | Biotech, Climate tech | United States | Investors | |
| VB Develops stroke therapeutics | $45M | Series A | Biotech | United States | Investors | |
| S SequentialCompany profile Develops non-invasive multi-omic testing platform for skin health and cosmetics using AI and microbiome analysis Develops non-invasive multi-omic testing platform for skin health and cosmetics using AI and microbiome analysis | $3.5M | Seed | Biotech, Healthtech | United States | Investors | |
| ST Surf TherapeuticsCompany profile Develops non-invasive ultrasound neuromodulation therapies to treat immune-mediated diseases Develops non-invasive ultrasound neuromodulation therapies to treat immune-mediated diseases | $6M | Seed | Biotech, Healthtech | United States | Investors | |
| B Develops liquid biopsy technology for early cancer detection | £15.8M | Series A | Biotech | United Kingdom | Investors | |
| CM Combat MedicalCompany profile Develops hyperthermic intravesical chemotherapy treatment for BCG unresponsive bladder cancer Develops hyperthermic intravesical chemotherapy treatment for BCG unresponsive bladder cancer | £2.6M | Series A | Biotech, Healthtech | United Kingdom | Investors | |
| W WaivCompany profile Develops AI-powered precision testing for better identification of patients in the clinic and in research Develops AI-powered precision testing for better identification of patients in the clinic and in research | $33M | Growth | Biotech, Healthtech | France | Investors Undisclosed | |
| LM Develops foundation models for biological sequences | $7M | Seed | Biotech | France | Investors Undisclosed | |
| S SeprifyCompany profile Develops cellulose-based alternative to titanium dioxide for cosmetics, food, and coatings Develops cellulose-based alternative to titanium dioxide for cosmetics, food, and coatings | €13.4M | Series A | Biotech, Climate tech | Switzerland | Investors | |
| UL Unreasonable LabsCompany profile Builds an AI reasoning engine to generate scientific hypotheses across chemistry, materials science, and biology for industrial R&D Builds an AI reasoning engine to generate scientific hypotheses across chemistry, materials science, and biology for industrial R&D | $13.5M | Seed | Biotech, AI | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
23rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.